Beam Therapeutics Inc. - BEAM STOCK NEWS

Beam Therapeutics (NASDAQ: BEAM) presented new data for its ESCAPE conditioning platform at the ASH Annual Meeting. The data demonstrated successful proof-of-concept in non-human primates (NHPs) for a non-genotoxic conditioning approach to treating sickle cell disease.

The platform consists of two investigational products: BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy designed to elevate fetal hemoglobin (HbF). Key findings showed long-term engraftment of base-edited hematopoietic stem cells, with HbF-containing cells reaching >80% post-transplant and γ-globin levels exceeding 40%. The treatment was well-tolerated, requiring no supportive care.

The company plans to initiate Phase 1-enabling studies by the end of 2024 for both sickle cell disease and beta-thalassemia applications.

Beam Therapeutics announced new data from its BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease (SCD). The trial showed promising results in seven treated patients with follow-up ranging from 1 to 11 months. Key achievements include:

- All patients achieved hemoglobin F levels >60% and hemoglobin S reduction to <40%
- Resolution of anemia and normalized hemolysis markers
- Rapid neutrophil (mean 17.1 days) and platelet (mean 19.1 days) engraftment
- Efficient cell collection with 1-2 mobilization cycles

The safety profile aligned with busulfan conditioning and autologous stem cell transplantation. One patient died from respiratory failure related to busulfan conditioning. No vaso-occlusive crises were reported post-engraftment. Currently, 11 patients have been dosed in the ongoing trial.

Beam Therapeutics (Nasdaq: BEAM) has appointed Sravan K. Emany as Chief Financial Officer, effective December 19, 2024. Emany joins from Ironwood Pharmaceuticals, where he served as CFO and COO. His extensive background includes leadership roles at Integra LifeSciences as Corporate VP of Commercial Excellence and Chief Strategy Officer, and nearly a decade in investment banking at Bank of America, where he led healthcare sector M&A as Managing Director.

CEO John Evans highlighted Emany's exceptional background in capital formation and allocation strategy, noting his importance in guiding Beam through its next growth phase as the company advances multiple clinical programs in hematology and genetic disease. Emany expressed enthusiasm about joining Beam's mission to transform genetic disease treatment through precision medicines.

Beam Therapeutics (Nasdaq: BEAM) has appointed Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., to its board of directors. Guindo brings over 25 years of pharmaceutical industry experience, having held senior executive roles in global strategy and commercial operations. Currently serving as chief marketing officer of Human Health at Merck, he leads the development and implementation of long-term strategy for the company's Human Health portfolio. Prior to his current role, Guindo served as executive vice president at Biogen and held various leadership positions at Merck in finance, sales, commercial, and marketing roles across multiple regions.

Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its participation in the 2024 Jefferies London Healthcare Conference. John Evans, CEO of Beam, will participate in a fireside chat on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. The presentation will be accessible via live webcast in the investor section of Beam's website and will remain archived for 60 days afterward.

Beam Therapeutics announced multiple presentations at the ASH Annual Meeting, including first clinical data from its BEAM-101 program for sickle cell disease. Initial results from the BEACON Phase 1/2 trial showed promising safety profile and efficacy in treated patients, with rapid fetal hemoglobin induction and sickle hemoglobin reduction. The company also presented positive preclinical data for its ESCAPE program, demonstrating successful non-genotoxic antibody-based conditioning in non-human primates. Additionally, preliminary data from the BEAM-201 trial showed complete response in 2 of 3 patients treated for T-cell lymphoblastic conditions.

Beam Therapeutics reported Q3 2024 financial results and program updates. The company has enrolled 35 patients and dosed eight in the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease. Initial clinical data will be presented at the upcoming ASH Annual Meeting. The first cohort dosing is completed for BEAM-302 in Alpha-1 Antitrypsin Deficiency, with data expected in 2025.

Financial highlights include $925.8M in cash and equivalents, with runway into 2027. Q3 net loss was $96.7M ($1.17 per share), with R&D expenses at $94.3M and G&A expenses at $26.5M. The company nominated development candidates BEAM-103 and BEAM-104 for its ESCAPE technology.

Beam Therapeutics (Nasdaq: BEAM) announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results. The company will also review abstracts accepted for presentation at the 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast will be available on the company's website, with a replay accessible for 60 days following the presentation.

Beam Therapeutics (Nasdaq: BEAM) reported significant progress in its clinical portfolio for Q2 2024. Key highlights include:

1. FDA clearance of IND for BEAM-301 in GSDIa
2. Over 20 patients enrolled and 6 dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease
3. First patient dosed in Phase 1/2 trial of BEAM-302 for AATD
4. $1.0 billion in cash, with runway into 2027

The company submitted initial clinical data for BEAM-101 and preclinical data for ESCAPE to ASH. Beam expects to report initial BEAM-302 clinical data in 2025 and commence BEAM-301 patient dosing in early 2025. Q2 financial results show R&D expenses of $87.0 million and a net loss of $91.1 million ($1.11 per share).